Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines

Experimental Hematology

Volumn 27, Issue 5, 1999, Pages 845-852

  Lu, Min ^a   Levin, Jack ^a   Sulpice, Eric ^a   Grand, Anabelle Sequeira Le ^a   Alemany, Mònica ^a   Caen, Jacques P ^a   Han, Zhong Chao ^b  

^a HÔPITAL LARIBOISIÈRE   (France)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Apoptosis; Arsenic trioxide; Bcl 2; Megakaryocytic leukemia cell lines

Indexed keywords

ARSENIC TRIOXIDE; DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; DNA FRAGMENT; DNA NUCLEOTIDYLEXOTRANSFERASE; PROTEIN BCL 2;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

APOPTOSIS; ARSENICALS; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HL-60 CELLS; HUMANS; IN SITU NICK-END LABELING; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; OXIDES; TUMOR CELLS, CULTURED;

EID: 0032923392     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(99)00014-4     Document Type: Article

References (32)

1. Sun H.D., Ma L., Hu X.C., Zhang T.D. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chinese Western Med. 12:1992;170.
2. Huang S.L., Guo A.X., Xiang Y., Wang X.B., Ling H.J., Fu L. Clinical study on the treatment of APL mainly with composite indigo naturalis tablets. Chin J Hematol. 16:1995;26.
3. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients Blood. 89:1997;3354.
4. Soignet S.L., Maslak P., Wang Z.-G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., Pandolfi P.P., Warrell R.P. Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 339:1998;1341.
5. Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 77:1991;1080.
6. 3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RARα/PML proteins Blood. 88:1996;1052.
7. 3 exerts dose-dependent dual effects on APL cells Blood. 89:1997;3345.
8. Kitamura K., Kiyoi H., Yoshida H., Tobita T., Takeshita A., Ohno R., Naoe T. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia. clinical and basic studies for the next generation Cancer Chemother Pharmacol. 40(suppl.):1997;S36.
9. Hassan H.T., Freund M. Characteristic biological features of human megakaryoblastic leukaemia cell lines. Leuk Res. 19:1995;589.
10. Ishida Y., Levin J., Baker G., Stenberg P.E., Yamada A., Sasaki H., Inoue T. Biological and biochemical characteristics of murine megakaryoblastic cell line L8057. Exp Hematol. 21:1993;289.
11. Sato T., Ota S., Kakuda H., Miura N., Niimi H., Ito M., Asai T., Tsuruo T., Fuse A. Expression of multidrug resistant gene (mdr-1/P-glycoprotein) in a megakaryoblastic cell line, CMK, and its enhancement during megakaryocytic differentiation. Leuk Lymphoma. 18:1995;515.
12. San Miguel J.F., Gonzalez M., Canizo M.C., Ojeda E., Orfao A., Caballero M.D., Moro M.J., Fisac P., Lopez Borrasca A. Leukemias with megakaryoblastic involvement. clinical, hematologic, and immunologic characteristics Blood. 72:1988;402.
13. Ogura M., Morishima Y., Ohno R., Kato Y., Hirabayashi N., Nagura H., Saito H. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood. 66:1985;1384.
14. Martin P., Papayannopoulou T. HEL cells. a new human erythroleukemia cell line with spontaneous and induced globin expression Science. 216:1982;1233.
15. Hong Y., Dumenil D., van der Loo B., Goncalves F., Vainchenker W., Erusalimsky J.D. Protein kinase C mediates the mitogenic action of thrombopoietin in c-Mpl-expressing UT-7 cells. Blood. 91:1998;813.
16. Ritchie A., Vadhan-Raj S., Broxmeyer H.E. Thrombopoietin suppresses apoptosis and behaves as a survival factor for the human growth factor-dependent cell line, M07e. Stem Cells. 14:1996;330.
17. Meyaard L., Otto S.A., Jonker R.R., Mijnster M.J., Keet R.P., Miedema F. Programmed death of T cells in HIV-1 infection. Science. 257:1992;217.
18. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493.
19. Portera-Cailliau C., Sung C.H., Nathans J., Adler R. Apoptotic photoreceptor cell death in mouse model of retinitis pigmentosa. Proc Natl Acad Sci U S A. 91:1994;974.
20. Wyllie A.H. Apoptosis and carcinogenesis. Eur J Cell Biol. 73:1997;189.
21. Rudel T., Bokoch G.M. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science. 276:1997;1571.
22. Dive C., Evans C.A., Whetton A.D. Induction of apoptosis-new targets for cancer chemotherapy. Semin Cancer Biol. 3:1992;417.
23. Sachs L., Lotem J. Control of programmed cell death in normal and leukemic cells. new implications for therapy Blood. 82:1993;15.
24. Kerr J.F., Winterford C.M., Harmon B.V. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 73:1994;2013.
25. Li X., Gong J., Feldman E., Seiter K., Traganos F., Darzynkiewicz Z. Apoptotic cell death during treatment of leukemias. Leuk Lymphoma. 13(suppl. 1):1994;65.
26. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med. 3:1997;614.
27. Yang E., Korsmeyer S.J. Molecular thanatopsis. a discourse on the Bcl-2 family and cell death Blood. 88:1996;386.
28. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1988;440.
29. Forkner C.E., McNair-Scott T.F. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA. 97:1931;305.
30. Kandel E.V., Leroy G.V. Chronic arsenical poisoning during the treatment of chronic myeloid leukemia. Arch Intern Med. 60:1937;846.
31. Sofuni T., Honma M., Hayashi M., Shimada H., Tanaka N., Wakuri S., Awogi T., Yamamoto K.I., Nishi Y., Nakadate M. Detection of in vitro clastogens and spindle poisons by the mouse lymphoma assay using the microwell method. interim report of an international collaborative study Mutagenesis. 11:1996;349.
32. König A., Wrazel L., Warrell R.P. Jr., Rivi R., Pandolfi P.P., Jakubowski A., Gabrilove J.L. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood. 90:1997;562.